
    
      The drug being tested in this study is called propiverine. Propiverine is being tested to
      evaluate Quality of Life (QoL) and improvement of OAB symptoms in people who take
      propiverine. The study will enroll approximately 1000 patients who the treating physician
      decided to treat with propiverine 15mg tablets or 30 mg regulated release capsules as part of
      their normal clinical practice. All participants will be asked to keep a voiding diary for 2
      consecutive days and to complete a QoL questionnaire after 1st visit and before each
      subsequent visit. This multi-centre trial will be conducted in Belgium. The overall time to
      participate in this study is up to 12 weeks. Participants will make 3 visits to their
      healthcare provider.
    
  